An assay to quantify species-specific anti-JC virus antibody levels in MS patients

Multiple Sclerosis Journal

Volumn 19, Issue 9, 2013, Pages 1137-1144

  Warnke, Clemens ^a,b   Pawlita, Michael ^c   Dehmel, Thomas ^a   Posevitz Fejfar, Anita ^d   Hartung, Hans Peter ^a   Wiendl, Heinz ^d   Kieseier, Bernd C ^a   Adams, Ortwin ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

BK virus; JC virus; Multiple sclerosis; progressive multifocal leukoencephalopathy; Tysabri

Indexed keywords

GLUTATHIONE TRANSFERASE; HUMAN IMMUNOGLOBULIN; JC VIRUS ANTIBODY; NATALIZUMAB; PROTEIN VP1; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADSORPTION; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; BK VIRUS; BLOOD ANALYSIS; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; CROSS REACTION; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOREACTIVITY; JC VIRUS; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATIENT CODING; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; QUALITATIVE ANALYSIS; QUANTITATIVE ASSAY; RISK ASSESSMENT; SERODIAGNOSIS; SPECIES DIFFERENCE;

BK VIRUS; JC VIRUS; MULTIPLE SCLEROSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; TYSABRI;

ADULT; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; BK VIRUS; CAPSID PROTEINS; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; JC VIRUS; MALE; MULTIPLE SCLEROSIS;

EID: 84880154458     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513475489     Document Type: Article

References (30)

1. Warnke C, Menge T, Hartung HP, et al. Natalizumab and progressive multifocal leukoencephalopathy: What are the causal factors and can it be avoided?. Arch Neurol. 2010 ; 67: 923-930
2. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: Updated recommendations for patient selection and monitoring. Lancet Neurol. 2011 ; 10: 745-758
3. Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: Lessons from 28 cases. Lancet Neurol. 2010 ; 9: 438-446
4. Monaco MC, Major EO. The link between VLA-4 and JC virus reactivation. Expert Rev Clin Immunol. 2012 ; 8: 63-72
5. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: Implications for PML risk stratification. Ann Neurol. 2010 ; 68: 295-303
6. Bozic C, Richman S, Plavina T, et al. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY-1. Ann Neurol. 2011 ; 70: 713-721
7. Warnke C, Adams O, Hartung HP, et al. Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: Recommendations for JC virus serology [in German]. Nervenarzt. 2011 ; 82: 1314-1319
8. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012 ; 366: 1870-1880
9. Trampe AK, Hemmelmann C, Stroet A, et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology. 2012 ; 78: 1736-1742
10. Warnke C, Subramanyam M, Bergström T, et al. Anti-JC virus antibody titer changes during natalizumab treatment in a Swedish MS cohort. American Academy of Neurology, 64th annual meeting ; New Orleans, LA, USA ;..
11. Lee P PT, Castro A, Berman M, et al. An enhanced ELISA for detection of anti-JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. 2nd annual meeting of the European Neurological Society ; Prague, Czech Republic ;..
12. Frisque RJ. Nucleotide sequence of the region encompassing the JC virus origin of DNA replication. J Virol. 1983 ; 46: 170-176
13. Randhawa P, Viscidi R, Carter JJ, et al. Identification of species-specific and cross-reactive epitopes in human polyomavirus capsids using monoclonal antibodies. J Gen Virol. 2009 ; 90: 634-639
14. Hamilton RS, Gravell M, Major EO. Comparison of antibody titers determined by hemagglutination inhibition and enzyme immunoassay for JC virus and BK virus. J Clin Microbiol. 2000 ; 38: 105-109
15. Stolt A, Sasnauskas K, Koskela P, et al. Seroepidemiology of the human polyomaviruses. J Gen Virol. 2003 ; 84: 1499-1504
16. Egli A, Infanti L, Dumoulin A, et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis. 2009 ; 199: 837-846
17. Plavina T, Berman M, Njenga M, et al. Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma. J Clin Virol. 2012 ; 53: 65-71
18. Kjaerheim K, Roe OD, Waterboer T, et al. Absence of SV40 antibodies or DNA fragments in prediagnostic mesothelioma serum samples. Int J Cancer. 2007 ; 120: 2459-2465
19. Sehr P, Muller M, Hopfl R, et al. HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. J Virol Methods. 2002 ; 106: 61-70
20. Sehr P, Zumbach K, Pawlita M. A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: Validation for HPV serology. J Immunol Methods. 2001 ; 253: 153-162
21. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 ; 50: 121-127
22. Waterboer T, Dondog B, Michael KM, et al. Dried blood spot samples for seroepidemiology of infections with human papillomaviruses, Helicobacter pylori, hepatitis C virus, and JC virus. Cancer Epidemiol Biomarkers Prev. 2012 ; 21: 287-293
23. Lucas RM, Hughes AM, Lay ML, et al. Epstein-Barr virus and multiple sclerosis. J Neurol Neurosurg Psychiatry. 2011 ; 82: 1142-1148
24. Knowles WA, Pipkin P, Andrews N, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol. 2003 ; 71: 115-123
25. Antonsson A, Green AC, Mallitt KA, et al. Prevalence and stability of antibodies to the BK and JC polyomaviruses: A long-term longitudinal study of Australians. J Gen Virol. 2010 ; 91: 1849-1853
26. Kean JM, Rao S, Wang M, et al. Seroepidemiology of human polyomaviruses. PLoS Pathog. 2009 ; 5:
27. Olsson T, Hillert J, Alfredsson L, et al. Anti-JCV antibody prevalence in a Swedish cohort of MS patients and non-MS-controls. 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis ; Gothenburg, Sweden ;..
28. Sundqvist E, Warnke C, Khademi M, et al. Genetic influence on anti-JC-virus antibody seropositivity in MS patients and controls. Poster presentation (P807), 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis ; Amsterdam, The Netherlands ;..
29. Warnke C, Dehmel T, Posevitz-Fejfar A, et al. Anti-JC-virus antibody prevalence in a German MS cohort. Mult Scler. 2012 ; 18: 1054-1055
30. Viscidi RP, Rollison DE, Sondak VK, et al. Age-specific seroprevalence of Merkel cell polyomavirus, BK virus, and JC virus. Clin Vaccine Immunol. 2011 ; 18: 1737-1743